Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Q3 Revenues, Income Up; CFO To Become CEO

NEW YORK, Oct. 27 (GenomeWeb News) - Qiagen reported revenues of $90.4 million for the third quarter of 2003 today, up from $76.9 million for the same period last year.


The Venlo, Netherlands-based nucleic acid technology company's net income for the quarter rose to $11.8 million, compared to $7.3 million in the third quarter of 2002. Qiagen's R&D expenses were nearly flat at $7.5 million, compared to $7.3 million for the same period last year.


Metin Colpan, the company's CEO, attributed the success in the quarter to the "ongoing shift in focus of academic and industrial R&D to functional genomics and clinical research," and said "the recently observed increases in pharmaceutical and biotech research spending allow us to look optimistically into 2004."


The company said that Colpan will transition from CEO to senior technology advisor beginning Jan. 1, and would join the company's supervisory board. Peer Schatz, who has served as chief financial officer of Qiagen for the past 11 years, has been named CEO.


As of Sept. 30, Qiagen had $75.3 million in cash and cash equivalents, compared to $44.9 million for the same period last year.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.